Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA UCSF
Dates
study started
completion around
Principal Investigator
by John M. Timmerman, MD (ucla)
Headshot of John M. Timmerman
John M. Timmerman

Description

Summary

Official Title

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

Details

Per protocol amendment 7, the secondary serum concentration endpoints were removed and will not be reported.

Keywords

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, programmed cell death 1 (PD-1, PD1), programmed cell death ligand 1 (PD-L1, PDL1), programmed cell death ligand 2 (PD-L2, PDL2), Lymphoma, Hematologic Neoplasms, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Pembrolizumab, Favezelimab

Eligibility

Locations

  • Ronald Reagan UCLA Medical Center (Radiological Sciences) ( Site 0007)
    Los Angeles California 90095 United States
  • University of California San Francisco ( Site 0023)
    San Francisco California 94143 United States
  • City of Hope ( Site 0001)
    Duarte California 91010 United States

Lead Scientist at University of California Health

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Merck Sharp & Dohme LLC
Links
Merck Clinical Trials Information Plain Language Summary
ID
NCT03598608
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 174 study participants
Last Updated